文献速递细菌感染、耐药与抗菌药物

新生儿万古霉素暴露目标的确定:多少才算足够?

Identification of vancomycin exposure target in neonates: how much is enough?
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该研究回顾性收集使用万古霉素的新生儿,构建群体药代动力学模型估算AUC,用logistic回归和分类回归树分析疗效相关变量及阈值。共131例新生儿纳入PPK建模,48例纳入疗效分析,其中13例感染MRSA;疗效最佳PK/PD目标为AUC0-24h/MIC≥331,谷浓度与AUC0-24h/MIC相关(r²=0.32)但个体差异大。

要点

  • 新生儿万古霉素疗效最佳PK/PD目标为AUC0-24h/MIC≥331。
  • 谷浓度与AUC0-24h/MIC相关(r²=0.32),但个体差异大。
  • 谷浓度不是疗效和AUC0-24h/MIC的可靠预测指标。

核心结论

  • AUC0-24h/MIC≥331是新生儿万古霉素疗效的最佳目标。
  • 谷浓度不是疗效和AUC0-24h/MIC的可靠预测指标,基于AUC指导的剂量调整在临床应用中更有价值。

研究设计与样本

  • 回顾性收集使用万古霉素的新生儿,构建群体药代动力学(PPK)模型估算AUC。
  • PPK建模纳入131例新生儿;疗效分析纳入48例患者,其中13例感染MRSA。
  • 采用logistic分析识别与疗效相关的变量,用分类回归树分析探索阈值,用线性回归模型分析第一天谷浓度与AUC/MIC的相关性。

主要发现

  • PPK建模纳入131例新生儿,协变量分析纳入月经后年龄和当前体重。
  • 疗效分析纳入48例患者,其中13例感染MRSA。
  • 疗效最佳PK/PD目标为AUC0-24h/MIC≥331。
  • 谷浓度与AUC0-24h/MIC相关(r²=0.32),但存在个体差异。
  • 给定谷浓度下,AUC0-24h/MIC差异可达2.5倍。

关键数值与推荐

  • 疗效最佳PK/PD目标:AUC0-24h/MIC≥331。
  • 谷浓度与AUC0-24h/MIC的线性回归r²=0.32。
  • 给定谷浓度下AUC0-24h/MIC差异可达2.5倍。

临床怎么用

  • 作者认为,基于AUC指导的剂量调整在临床应用中更有价值。
  • 作者指出,谷浓度不是疗效和AUC0-24h/MIC的可靠预测指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Vancomycin is commonly used in neonates with the same pharmacokinetics/pharmacodynamics (PK/PD) target as adults. However, no evidence supports this practice, and the association between trough concentrations and treatment outcomes has been widely questioned. This study aimed to identify the optimal PK/PD predictor and assess the correlation between AUC/MIC, trough concentration and the vancomycin efficacy in neonates. METHODS: This study retrospectively collected neonates who used vancomycin and constructed a population pharmacokinetic (PPK) model to estimate the AUC. Logistic analyses were used to identify the variables related to efficacy. Classification and regression tree analysis was used to explore thresholds. The correlation between trough concentration and AUC/MIC on the first day was analysed using a linear regression model. RESULTS: PPK modelling involved 131 neonates. Postmenstrual age and current weight were included in the covariate analysis. Forty-eight patients were included in the efficacy analysis, 13 of whom were infected with MRSA. The best-performance PK/PD target for efficacy was AUC0-24h/MIC ≥ 331. The trough concentration was correlated with AUC0-24h/MIC (r2 = 0.32), but individual differences existed. AUC0-24h/MIC ranged up to 2.5-fold for a given trough concentration. CONCLUSIONS: AUC0-24h/MIC ≥ 331 was the optimal target of vancomycin efficacy in neonates. The trough concentration was not a reliable predictor of efficacy and AUC0-24h/MIC. AUC-guided dosage adjustments are more valuable in clinical applications.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gao Y, Wu T, Pu L, et al. Identification of vancomycin exposure target in neonates: how much is enough? J Antimicrob Chemother. 2024. PMID: 39450856. doi:10.1093/jac/dkae374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。